These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 32000868)

  • 1. Five pillars for societal perspective.
    Drost RMWA; Paulus ATG; Evers SMAA
    Int J Technol Assess Health Care; 2020 Apr; 36(2):72-74. PubMed ID: 32000868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can the Consideration of Societal Costs Change the Recommendation of Economic Evaluations in the Field of Rare Diseases? An Empirical Analysis.
    Aranda-Reneo I; Rodríguez-Sánchez B; Peña-Longobardo LM; Oliva-Moreno J; López-Bastida J
    Value Health; 2021 Mar; 24(3):431-442. PubMed ID: 33641778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CONCEPTUALIZATIONS OF THE SOCIETAL PERSPECTIVE WITHIN ECONOMIC EVALUATIONS: A SYSTEMATIC REVIEW.
    Drost RMWA; van der Putten IM; Ruwaard D; Evers SMAA; Paulus ATG
    Int J Technol Assess Health Care; 2017 Jan; 33(2):251-260. PubMed ID: 28641592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are intersectoral costs considered in economic evaluations of interventions relating to sexually transmitted infections (STIs)? A systematic review.
    Schnitzler L; Evers SMAA; Jackson LJ; Paulus ATG; Roberts TE
    BMC Public Health; 2022 Nov; 22(1):2180. PubMed ID: 36434561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-utility analysis from a societal perspective.
    Johannesson M; O'Conor RM
    Health Policy; 1997 Mar; 39(3):241-53. PubMed ID: 10165464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness Analysis of Erenumab Versus OnabotulinumtoxinA for Patients with Chronic Migraine Attacks in Greece.
    Giannouchos TV; Mitsikostas DD; Ohsfeldt RL; Vozikis A; Koufopoulou P
    Clin Drug Investig; 2019 Oct; 39(10):979-990. PubMed ID: 31302899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Future Costs, Fixed Healthcare Budgets, and the Decision Rules of Cost-Effectiveness Analysis.
    van Baal P; Meltzer D; Brouwer W
    Health Econ; 2016 Feb; 25(2):237-48. PubMed ID: 25533778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Making a case for employing a societal perspective in the evaluation of Medicaid prescription drug interventions.
    Roy S; Madhavan SS
    Pharmacoeconomics; 2008; 26(4):281-96. PubMed ID: 18370564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of components included in published societal perspective or QALY outcome economic analyses for antiepileptic drug treatment in chronic epilepsy.
    Roberts MH; Takeda MY; Kindilien S; Barqawi YK; Borrego ME
    Expert Rev Pharmacoecon Outcomes Res; 2018 Oct; 18(5):487-503. PubMed ID: 29911955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How is the Societal Perspective Defined in Health Technology Assessment? Guidelines from Around the Globe.
    Avşar TS; Yang X; Lorgelly P
    Pharmacoeconomics; 2023 Feb; 41(2):123-138. PubMed ID: 36471131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporating Affordability Concerns Within Cost-Effectiveness Analysis for Health Technology Assessment.
    Lomas JRS
    Value Health; 2019 Aug; 22(8):898-905. PubMed ID: 31426931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Total costs of treating venous thromboembolism: implication of different cost perspectives in a Danish setting.
    Nielsen A; Poulsen PB; Dybro L; Kloster B; Lorentzen A; Olsen J; Kümler T
    J Med Econ; 2019 Dec; 22(12):1321-1327. PubMed ID: 31516054
    [No Abstract]   [Full Text] [Related]  

  • 13. Striving for a Societal Perspective: A Framework for Economic Evaluations When Costs and Effects Fall on Multiple Sectors and Decision Makers.
    Walker S; Griffin S; Asaria M; Tsuchiya A; Sculpher M
    Appl Health Econ Health Policy; 2019 Oct; 17(5):577-590. PubMed ID: 31098947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How to Appropriately Extrapolate Costs and Utilities in Cost-Effectiveness Analysis.
    Bojke L; Manca A; Asaria M; Mahon R; Ren S; Palmer S
    Pharmacoeconomics; 2017 Aug; 35(8):767-776. PubMed ID: 28470594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Web-Based Computer-Tailored Alcohol Prevention Program for Adolescents: Cost-Effectiveness and Intersectoral Costs and Benefits.
    Drost RM; Paulus AT; Jander AF; Mercken L; de Vries H; Ruwaard D; Evers SM
    J Med Internet Res; 2016 Apr; 18(4):e93. PubMed ID: 27103154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A dollar is a dollar is a dollar--or is it?
    Brouwer WB; van Exel NJ; Baltussen RM; Rutten FF
    Value Health; 2006; 9(5):341-7. PubMed ID: 16961552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MEDICAL DEVICE PRICES IN ECONOMIC EVALUATIONS.
    Akpinar I; Jacobs P; Husereau D
    Int J Technol Assess Health Care; 2015 Jan; 31(1-2):86-9. PubMed ID: 25989920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the National Institute for Health and Care Excellence Diagnostics Assessment Program Decisions: Incremental Cost-Effectiveness Ratio Thresholds and Decision-Modifying Factors.
    Chen G; Peirce V; Marsh W
    Value Health; 2020 Oct; 23(10):1300-1306. PubMed ID: 33032773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation approaches for new technology.
    Papatheofanis FJ
    IEEE Eng Med Biol Mag; 2003; 22(3):16-7. PubMed ID: 12845811
    [No Abstract]   [Full Text] [Related]  

  • 20. The broader societal impacts of COVID-19 and the growing importance of capturing these in health economic analyses.
    Schnitzler L; Janssen LMM; Evers SMAA; Jackson LJ; Paulus ATG; Roberts TE; Pokhilenko I
    Int J Technol Assess Health Care; 2021 Mar; 37():e43. PubMed ID: 33686927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.